



February 15, 2022

To, The Manager (Corporate Relations) BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001 Scrip Code: 506390

Sub: Open offer for acquisition of up to 6,001,268 fully paid-up equity shares of face value of INR 10 each ("Equity Shares") of Clariant Chemicals (India) Limited ("Target Company") from the Public Shareholders of the Target Company pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("Takeover Regulations", and such open offer for acquisition referred as "Open Offer").

Dear Sir/Madam,

With regard to the captioned Open Offer, the Acquirer has appointed ICICI Securities Limited, as the Manager to the Offer pursuant to and in accordance with, Regulation 12(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("SEBI (SAST) Regulations").

A Detailed Public Statement was published on January 10, 2022, a Draft Letter of Offer was filed on January 17, 2022 and Letter of Offer was filed on February 7, 2022.

In accordance with Takeover Regulation number 18 (7), a pre offer opening advertisement cum corrigendum and addendum dated February 14, 2022, was published on February 15, 2022, on in the same newspapers where the Details Public Announcement of the open offer was published (**Attached as Annexure A**)

Terms not defined herein shall have the meaning ascribed to them under the detailed public statement and the draft letter of offer, including amendments thereto.

Yours sincerely,

For ICICI Securities Limited

Sameer Purohit Vice President

SEBI Registration: INM000011179 CIN No.: L67120MH1995PLC086241

ICICI Securities Limited
Registered Office:
ICICI Venture House
Appasaheb Marathe Marg,
Prabhadevi, Mumbai - 400025, India
Tel (91 22) 6807 7100

Fax (91 22) 6807 7801

Website Address: www.icicisecurities.com

FINANCIAL EXPRESS

MEDICO INTERCONTINENTAL LIMITED CIN: L24100GJ1984PLC111413

Regd. Office: 1-5th Floor, Adit Raj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad, Gujarat - 380015 **Phone:** 079 2674 2739

Email: mail@medicointercontinental.com **Website:** www.medicointercontinental.com

Extracts of Unaudited Standalone and Consolidated Financial Results for the Quarter and nine months ended 31st December, 2021. (Amt. in Lakhs except for the EPS)

		Stanuaione			Consolidated			
Particulars	Quarter ended 31.12.2021 (Unaudited)	Nine Months ended 31.12.2021 (Unaudited)	Corresponding 3 months ended in previous year on 31.12.2020 (Unaudited)	ended	Nine Months ended 31.12.2021 (Unaudited)	Corresponding months ended i previous year o 31.12.2020 (Unaudited)		
Total income from operations (net)	1015.81	3156.03	844.46	1767.60	5992.97	1616.62		
Net Profit/(Loss)for the period								
(before tax and exceptional items)	45.29	135.33	41.25	100.24	299.15	88.53		
Net Profit/(Loss)for the period before tax								
(after exceptional items)	45.29	135.33	41.25	100.24	299.15	88.53		
Net Profit / (Loss) for the period after tax	33.80	100.93	31.13	74.77	223.14	66.53		
Total Comprehensive Income for the period	33.80	100.93	31.13	74.77	223.14	66.53		
Paid-up Equity Share Capital								
(Share of Rs. 10/- each)	324.90	324.90	324.90	324.90	324.90	324.90		
Earning per equity share								
Basic	1.04	3.11	0.96	2.30	6.87	2.05		
Diluted	1.04	3.11	0.96	2.30	6.87	2.05		

The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Unaudited Financial Results along with Limited Review Report for the quarter and nine months ended is available on the website of the Stock Exchange (www.bseindia.com) and on the website of the Company (www.medicointercontinental.com).

The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on February 14, 2022. The Statutory Auditors have carried out a limited review of the aforesaid financial results as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Financial Results of the Company has been prepared in accordance with Indian Accounting Standards (IND AS) notified under the Companies (Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and other accounting principles generally accepted in India. For Medico Intercontinental Limited

Samir Shah

Date: 14/02/2022 Place: Ahmedabad

Managing Director DIN: 03350268

SUNSHIELD

SUNSHIELD CHEMICALS LIMITED

Corporate Identity Number: L99999MH1986PLC041612 CHEMICALS LTD Regd. Office: 1501-A, Universal Majestic, P.L. Lokhande Marg, behind RBK International School,

Chembur-West, Mumbai-400 043. | Phone No. 25550126 E Mail: investorservices@sunshieldchemicals.com | Website: www.sunshieldchemicals.com

Extract of unaudited financial results for the quarter and nine months ended 31 December, 2021

Sr. No.	Particulars	Three months ended 31/12/2021 Unaudited	Previous three months ended 30/09/2021 Unaudited	Corresponding three months ended 31/12/2020 Unaudited	Nine months ended 31/12/2021 Unaudited	Corresponding Nine months ended 31/12/2020 Unaudited	Year ended 31/03/2021 Audited
1	Total income from operations	5,800	5,880	5,405	17,746	14,719	19,891
2	Net Profit for the period/year (before tax and exceptional items)	560	655	544	1,687	1,195	1,662
3	Net Profit for the period/year (before tax after exceptional items)	560	655	544	3,469	1,195	1,662
4	Net Profit for the period/year after tax	379	458	394	2,468	1,088	1,418
5	Total Comprehensive Income for the period/year	382	462	391	2,480	1,079	1,431
6	Paid -up equity share capital (face value of Rs.10/- each)	735	735	735	735	735	735
7	Other Equity excluding revaluation reserve (as per last audited balance sheet)	200000000000000000000000000000000000000	20.000000000000000000000000000000000000	120000000000000000000000000000000000000			1,879
8	Basic & Diluted Earnings per Share (of Rs.10/- each) (* not annualized) -in Rupees	5.15*	6.23*	5.36*	33.57*	14.79*	19.29

The Unaudited financial Results for the quarter/nine month ended 31 December 2021 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective Meetings held on 14 February 2022, In Compliances with Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 ("SEBI Regulations") a limited review of the above results has been carried out by statutory auditors of the Company.

The above is an extract of the detailed format of Quarterly/Nine Month Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/nine Month Financial Results are available on the Stock Exchange website (www.bseindia.com) and on the Company's website www.sunshieldchemicals.com For and on behalf of the Board of Directors SUNSHIELD CHEMICALS LIMITED

Mumbai, 14 February 2022

Virendrasingh Baidwal Managing Director

Director



BF UTILITIES LIMITED

Regd. Off.: Mundhwa, Pune Cantonment, Pune-411036 CIN: L40108PN2000PLC015323

Tel: 91 20 26725257/59 Email: Secretarial@bfutilities.com Website: www.bfutilities.com Extract of Statement of Unaudited Consolidated Financial Results for the

Sr. No.	Particulars	Quarter ended 31-12-2021	Nine Months Ended 31-12-2021	Quarter ended 31-12-2020	
	0.0000000000000000000000000000000000000	Unaudited	Unaudited	Audited	
1	Total Income from operations	14,133.03	33,467.88	11,139.41	
2	Net Profit / (Loss) for the period (before tax and exceptional items)	4,896.01	6,008.53	1,907.24	
3	Net Profit / (Loss) for the period before tax (after exceptional items)	4,896.01	6,008.53	1,907.24	
4	Net Profit / (Loss) for the period after tax (after exceptional items)	4,618.19	5,473.06	1,710.96	
5	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	4,616.86	5,486.98	1,714.88	
6	Equity Share Capital	1,883.38	1,883.38	1,883.38	
7	Earnings Per Share in Rupees (Face value of ₹ 5 each)	7.000000000000000000000000000000000000	1,704,000,000	223230000130000	
	Basic:	6.00	7.82	2.31	
	Diluted:	6.00	7.82	2.31	

Note: The above is an extract of the detailed format of Quarterly and Nine Months ended Consolidated Financial Results filed with the Stock Exchanges under Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on www.nseindia.com www.bseindia.com and on the Company website www.bfutilities.com. For BF Utilities Limited B S Mitkari

Place: Pune

Date: 14th February, 2022 DIN: 03632549

LOKESH MACHINES LIMITED

Regd. Office: B-29, EEIE STAGE-II, Balanagar, Hyderabad- 500037 E-mail Id:cosecy@lokeshmachines.com;

Website:www.lokeshmachines.com CIN:L29219TG1983PLC004319

EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 0N 31st DECEMBER, 2021

		LICE VA TITLE		esser our management	(Rs in lakhs)
	Quarter ended		Nine months ended	Year ended	
Particulars	31.12.2021 (UNAUDITED)	30.09.2021 (UNAUDITED)	31.12.2020 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2021 (AUDITED)
Total Income from Operations	5460.83	4930.25	4073.47	13662.46	15021.45
Net Profit/(Loss) for the period (before tax and exceptional items)	261.49	222.75	213.24	504.70	542.06
Net Profit/(Loss) for the period before tax (after exceptional items)	261.49	222.75	213.24	504.70	542.06
Net Profit/(Loss) for the period after tax (after exceptional items)	188.27	160.38	153.53	363.38	396.15
Total comprehensive income for the period(Comprehensive Profit/Loss for the period (after Tax) and Other Comprehensive Income (after tax)	188.27	204.38	153.53	363.38	425.72
Equity Share Capital	1789.68	1789.68	1789.68	1789.68	1789.68
Earnings Per Share :	- 500000		200000000		720000 8
Basic : (Rs)	1.05	0.90	0.86	2.03	2.21
Diluted : (Rs)	1.05	0.90	0.86	2.03	2.21

- The above is an extract of the detailed format of Un-Audited financial results for Quarter and nine months ending on December 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Un-Audited financial results for the guarter and nine months ending on December 31, 2021 are available on the Stock Exchanges Website i.e. on BSE & NSE website and on the Company's Website: www.lokeshmachines.com.
- 2. The above Un-Audited financial results have been reviewed by the audit committee and approved by the board of directors at their meeting held on 14th February, 2022. The financial results have also been subjected to Limited Review by the Statutory Auditor.
- 3. The results for the period ended December 31, 2021 are not comparable as such with that of the period ended December 31, 2020 as the operations for the period ended December 31, 2020 were partially suspended on account of the lockdown announced by the Government of India consequent to the outbreak of the COVID-19 pandemic

Place: Hyderabad Date: 14.02.2022 For and behalf of Board of Directors M. Lokeswara Rao Managing Director

For All Advertisement Booking

Call: 0120-6651214

ADVERTISEMENT IN ACCORDANCE WITH REGULATION 18(7) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 (AS AMENDED) ("SEBI (SAST) REGULATIONS") AND CORRIGENDUM TO THE DETAILED PUBLIC STATEMENT AND DRAFT LETTER OF OFFER ("CORRIGENDUM") WITH RESPECT TO THE OPEN OFFER TO THE PUBLIC SHAREHOLDERS OF

Clariant Chemicals (India) Limited

Registered Office: Reliable Tech Park, Gut No. 31, Village Elthan, off Thane Belapur Road, Airoli, Navi Mumbai 400 708, Maharashtra, India Tel: +91-22-7125 1000, Fax: +91-22-7125 1201, CIN: L24110MH1956PLC010806

Open offer for acquisition of up to 6,001,268 (six million one thousand two hundred sixty-eight) fully paid-up equity shares of face value of INR 10 each ("Equity Shares"), representing 26.00% of the Voting Share Capital of Clariant Chemicals (India) Limited ("Target Company") from the Public Shareholders of the Target Company by Luxembourg Investment Company 428 S.à r.l. ("Acquirer"), together with Luxembourg Investment Company 426 S.à r.l. ("PAC 1"), Clariant AG ("PAC 2"), Heubach Holding GmbH ("PAC 3"), Ravi Kapoor ("PAC 4"), Heubach Verwaltungs GmbH ("PAC 5") and Colorants International AG ("PAC 6" and, along with PAC 1, PAC 2, PAC 3, PAC 4 and PAC 5, the "PACs"), in their capacity as persons acting in concert with the Acquirer, pursuant to and in compliance with the requirements of the SEBI (SAST) Regulations at a price of INR 493.84 (Rupees four hundred ninety three and eighty four Paisa) per Equity Share ("Open Offer" / "Offer").

This pre-offer opening public announcement cum corrigendum and addendum to | 6. the LoF (as defined below) ("Pre-Offer Opening Public Announcement cum Corrigendum and Addendum") is being issued by ICICI Securities Limited ("Manager to the Offer"), for and on behalf of the Acquirer and PACs, in respect of the Open Offer.

This Pre-Offer Opening Public Announcement cum Corrigendum and Addendum should be read in continuation of and in conjunction with (a) the public announcement dated June 14, 2021 ("Public Announcement" or "PA"); (b) the detailed public statement dated January 8, 2022, which was published on January 10, 2022, in Financial Express (English - All Editions), Jansatta (Hindi - All Editions) and Navshakti (Marathi, Mumbai edition) ("DPS"); (c) the draft letter of offer dated January 17, 2022 ("DLOF"); (d) the corrigendum to the DPS and DLOF in connection with the Offer, dated January 20, 2022, which was published in Financial Express (English, all editions), Jansatta (Hindi, all editions), and Navshakti (Marathi, Mumbai edition) ("Corrigendum"); and (e) the letter of offer dated February 7, 2022 ("LoF").

Capitalised terms used but not defined in this Pre-Offer Opening Public Announcement cum Corrigendum and Addendum shall have the meaning assigned to such terms in the LoF.

- 1. Offer Price: The Offer Price is INR 493.84 (Rupees four hundred ninety three and eighty four Paisa) per Offer Share consisting of INR 466.84 (Rupees four hundred sixty six and eighty four Paisa only) per Equity Share plus interest of INR 26.99 (Rupees twenty six and ninety nine Paisa) per Equity Share, computed at the rate of 10% per annum, for the period between June 11, 2021 (being the date of the SPA) and January 8, 2022 (being the date of the DPS), in terms of Regulation 8(12) of the SEBI (SAST) Regulations. There has been no revision in the Offer Price.
 - For further details, relating to the Offer Price, please refer to section titled "Offer Price And Financial Arrangements - Justification of Offer Price" on Page 53 of the LoF.
- Recommendations of the committee of independent directors of the Target Company: The committee of independent directors of the Target Company ("IDC") was approved on February 12, 2022 and published on February 14, 2022 in the same newspapers where the DPS was published. The relevant extract of the recommendation of the IDC is given below:

Members of the Mr. Kewal Handa, Chairperson

Committee of Mr. Sunirmal Talukdar, Member Independent Directors Dr. (Mrs.) Indu Shahani, Member

Recommendation on The IDC has perused the Detailed Public Statement fair and reasonable

the Open offer, as to dated January 8, 2022 which was published on whether the offer is January 10, 2022 and the Letter of Offer dated February 7, 2022, and other publicly available documents as released and published by the Acquirer and PACs. RBSA Capital Advisors LLP vide their report dated

> their analysis, the open offer price is fair to the shareholders of CCIL, from a financial perspective. The analysis was presented to the IDC at its meeting held on February 12, 2022. Based on the above, the IDC is of opinion that

> February 12, 2022 have opined that based on

the open offer price to the public shareholders of the Target Company is in compliance with the Regulations and to that extent is fair and reasonable. The Eligible Shareholders are advised to independently evaluate the Open Offer and take an informed decision on the Open Offer.

for recommendation

Summary of reasons | This is an Open Offer for acquisition of publicly held equity shares.

> The IDC has sought an external advice from RBSA Capital Advisors LLP, who have opined that based on their analysis, the open offer price is fair to the shareholders of CCIL, from a financial perspective. The IDC has reviewed Detailed Public Statement dated January 8, 2022 which was published on January 10, 2022, Letter of Offer dated February 7, 2022, Fairness Opinion Report by RBSA Capital Advisors LLP and other publicly available documents issued by the Manager to the Open Offer on the behalf of the Acquirer and PACs.

> offer price offered by the Acquirer is in line with the SAST Regulations and appears to be fair and reasonable prima facie. The Eligible Shareholders are advised to

> Based on the review, the IDC is of opinion that the

independently evaluate the Open Offer and take an informed decision on the Open Offer. Details of Independent RBSA Capital Advisors LLP

Advisors, if any.

Address: 912, Venus Atlantis Corporate Park, , Anandnagar, Prahladnagar, Ahmedabad Gujarat, 380015 India. SEBI Reg. No.: INM000011724

Other details of the Offer:

- 3.1 The Offer is being made under Regulation 3(1) and Regulation 4 read with Regulation 5(1) of the SEBI (SAST) Regulations to the Public Shareholders of the Target Company.
- 3.2 The Offer is not a competing offer in terms of Regulation 20 of SEBI (SAST) Regulations. There has been no competing offer to the Offer and the last date for making such competing offer has expired. The Offer is not conditional upon any minimum level of acceptance in terms of Regulation 19(1) of SEBI (SAST) Regulations.
- 3.3 The dispatch of the LoF to all the Public Shareholders of the Target Company holding Equity Shares as on the Identified Date (being February 2, 2022) has been completed (through electronic or physical mode) by February 9, 2022. It is clarified that all Public Shareholders (registered or unregistered) of Equity Shares are eligible to participate in the Open Offer at any time before the Offer Closing Date.
- 3.4 Please note that a copy of the LoF (which inter alia includes detailed instructions in relation to the procedure for acceptance and settlement of the Open Offer on page 61 of the LoF, as well as the Form of Acceptance and SH-4) is also available on the websites of SEBI at https://www.sebi.gov.in. Registrar to the Offer at www.linkintime.co.in, Manager to the Offer at www.icicisecurities.com and BSE at www.bseindia.com.
- 3.5 In case of non-receipt / non-availability of the Form of Acceptance, a Public Shareholder may participate in the Open Offer: (i) by using the Form of Acceptance obtained in the manner described above; or (ii) by providing their application in plain paper in writing signed by all shareholder(s), stating name, address, number of Equity Shares held, client ID number. DP name, DP ID number, number of Equity Shares tendered and other relevant documents as mentioned in LoF.
- 3.6 Public Shareholders have to ensure that their order is entered in the electronic platform to be made available by BSE or NSE before the closure of the Tendering Period.
- 4. Instructions to the Public Shareholders:
 - 4.1 In case the Equity Shares are held in physical form: Public Shareholders holding Equity Shares in physical form may participate in the Open Offer through their respective Selling Broker by providing the relevant information and documents as mentioned in paragraph 8.18 on page 65 of the LoF.
 - 4.2. In case the Equity Shares are held in dematerialised form: Public Shareholders who are holding Equity Shares in dematerialised form and desire to tender their Equity Shares in dematerialised form under the Offer would have to do so through their respective Selling Brokers by giving the details of Equity Shares they intend to tender under the Offer and as per the procedure specified in paragraph 8.17 on page 64 of the LoF.
- 5. In terms of Regulation 16(1) of the SEBI (SAST) Regulations, the DLOF was submitted to SEBI on January 17, 2022. SEBI, vide its letter no. SEBI/HO/ CFD/DCR-1/P/OW/2022/03863/1 dated January 31, 2022 ("Observation Letter"), issued its observations on the DLOF. These comments and other key changes (occurring after the date of the Public Announcement) have been incorporated in the LoF.

- Material Updates: The comments specified by SEBI in the Observation Letter and certain changes (occurring after the date of DLOF) which may be material have been incorporated in the LoF.
- Status of Statutory and Other Approvals:

As of the date of the LoF and to the best of the knowledge of the Acquirer and PACs, there are no statutory or other approvals required to complete the Offer. However, in case any statutory approvals are required by the Acquirer / the PACs at a later date before closure of the Tendering Period, the Offer shall be subject to such statutory approvals and the Acquirer shall make the necessary applications for such statutory approvals. Please also refer to paragraph 7.3 beginning on page 60 of LoF for further details.

Under paragraph 9 - "Documents for Inspection" on page 80 of the LoF, the following document to be included:

Share purchase agreement dated June 11, 2021.

Revised Schedule of Activities: The schedule of major activities under the Offer is set out below:

NAME OF ACTIVITY	SCHEDULE OF ACTIVITIES* (DAY AND DATE)	REVISED SCHEDULE OF ACTIVITIES (DAY AND DATE)	
Public Announcement Date	Monday, June 14, 2021	Monday, June 14, 2021	
Detailed Public Statement (DPS) Date	Saturday, January 8, 2022	Saturday, January 8, 2022	
Publication of the DPS in newspapers	Monday, January 10, 2022	Monday, January 10, 2022	
Filing of the Draft Letter of Offer with SEBI	Monday, January 17, 2022	Monday, January 17, 2022	
Last date for public announcement for competing offer(s)	Monday, 31 January, 2022	Monday, 31 January, 2022	
Last date for receipt of comments from SEBI on the Draft Letter of Offer (in the event SEBI has not sought clarification or additional information from the Manager to the Offer)	Tuesday, 8 February, 2022	Monday, 31 January, 2022**	
Identified Date*	Thursday, 10 February, 2022	Wednesday, 2 February, 2022	
Last date for dispatch of the Letter of Offer to the Public Shareholders of the Target Company	Thursday, 17 February, 2022	Wednesday, 9 February, 2022	
Last date by which a committee of independent directors of the Target Company is required to give its recommendation to the Public Shareholders of the Target Company for this Offer	Tuesday, 22 February, 2022	Monday, 14 February, 2022	
Last date for upward revision of the Offer Price	Tuesday, 22 February, 2022	Monday, 14 February, 2022	
Date of publication of Offer Opening Public Announcement, in the newspapers in which the DPS has been published	Wednesday, 23 February, 2022	Tuesday, 15 February, 2022	
Date of commencement of the Tendering Period	Thursday, 24 February, 2022	Wednesday, 16 February, 2022	
Date of closure of the Tendering Period	Thursday, 10 March, 2022	Wednesday, 2 March, 2022	
Last date of communicating the rejection/acceptance and completion of payment of consideration or return of Equity Shares to the Public Shareholders of the Target Company	Friday, 25 March, 2022	Wednesday, 16 March, 2022	
Last date for publication of post- Offer public announcement in the newspapers in which the DPS has been published	Friday, 1 April, 2022	Thursday, 24 March, 2022	

Shareholders as on such date to whom the Letter of Offer would be sent. It is clarified that all holders (registered or unregistered) of Equity Shares (except the Acquirer, the promoter, members of the promoter group of the Target Company, the PACs, the parties to the Transaction Documents, and any persons deemed to be acting in concert with any of the parties mentioned above, pursuant to and in compliance with the SEBI SAST Regulations) are eligible to participate in the Offer any time during the Tendering Period.

**Actual date of receipt of SEBI's final observations on the DLOF.

10. Other Information:

- 10.1 The Acquirer and the PACs including their respective directors accept full responsibility for the obligations of the Acquirer and the PACs as laid down in terms of the SEBI (SAST) Regulations and for the information (other than such information pertaining to the Target Company, which has been sourced from publicly available sources or from information published or as has been provided or confirmed by the Target Company) contained in this Pre-Offer Opening Public Announcement cum Corrigendum and Addendum. 10.2 In this Pre-Offer Opening Public Announcement cum Corrigendum and
- Addendum all references to "Rs." or "INR" are references to the Indian Rupee. 10.3 This Pre Offer Opening Public Announcement cum Corrigendum
- and Addendum would also be available on websites of SEBI at https://www.sebi.gov.in and Manager to the Offer at www.icicisecurities.com.

MANAGER TO THE OFFER



ICICI Venture House. Appasaheb Marathe Marg,

Prabhadevi, Mumbai 400 025, Maharashtra, India

Contact Person: Sameer Purohit/Gaurav Mittal Tel: +91 22 6807 7100

Fax: +91 22 6807 7801 E-mail: clariantindia.openoffer@icicisecurities.com

Website: www.icicisecurities.com SEBI Registration Number: INM000011179

REGISTRAR TO THE OFFER

LINKIntime

LINK INTIME INDIA PRIVATE LIMITED C-101, 1st Floor, 247 Park,

Lal Bahadur Shastri Marg,

Vikhroli (West), Mumbai 400 083, Maharashtra, India

Contact Person: Mr. Sumeet Deshpande Tel: +91 22 4918 6200

Fax: +91 22 4918 6195

E-mail: clariantchem.openoffer@linkintime.co.in

Website: www.linkintime.co.in

SEBI Registration Number: INR000004058

Place: Mumbai Date: February 14, 2022

PRESSMAN

financialexp.epap.in